Companies · Biotechnology
LISHUI · Biotechnology
Diligence memoA one-page analyst read on AnPac Bio-Medical Science Co., Ltd. — recommendation, valuation, rhythm, risks.→AnPac Bio-Medical Science Co., Ltd. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
AnPac Bio-Medical Science Co., Ltd. is one of 4293 Biotechnology companies tracked from LISHUI. By capital raised it ranks mid-pack (ahead of 42% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 42% of sector peers (real $). Modeled value above 31% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #67 of 207.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Mesentech Inc. | Seed | $3.9M | $65.7M | 4.61× |
| Marlinspike Therapeutics, Inc. | Seed | $3.5M | $64.4M | 4.52× |
| Microbial Machines, Inc. | Seed | $3.9M | $63.7M | 4.47× |
| Pearl Diagnostics, Inc. | Seed | $3.5M | $62.9M | 4.41× |
| Crossfire Medical Inc | Seed | $3.0M | $57.5M | 4.04× |
| Design Pharmaceuticals, Inc. | Seed | $3.0M | $57.0M | 4.00× |
| Tekv Holdings LLC | Seed | $4.0M | $55.5M | 3.89× |
| Mi-Helper, Inc. | Seed | $4.0M | $50.9M | 3.58× |
| Thelium Therapeutics Inc. | Seed | $3.1M | $50.7M | 3.56× |
| Turtle Health, Inc. | Seed | $2.7M | $49.1M | 3.45× |
| Accufix Holdings, Inc. | Seed | $4.2M | $46.7M | 3.28× |
| Kyttaro Ltd | Seed | $5.2M | $45.5M | 3.20× |
| AnPac Bio-Medical Science Co., Ltd. this company | Seed | $4.7M | $23.1M | 1.62× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $265K | 2020-08-07 | $1.5M | $13.8M | 90% |
| Seed | $1.4M | 2022-05-16 | $7.0M | $22.0M | 90% |
| Seed | $1.5M | 2022-05-27 | $7.5M | $23.2M | 90% |
| Seed | $1.5M | 2022-05-30 | $7.5M | $23.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Edward Tang | — | 1 other | 2020-08 |
| Lin Yu | — | 1 other | 2020-08 |
| Aidong Chen | — | — | 2022-05 |
| Chang Yu | — | — | 2022-05 |
| Chris Chang Yu | — | — | 2022-05 |
| Feng Guo | — | — | 2020-08 |
| He Yu | — | — | 2020-08 |
| Jianhua Shao | — | — | 2022-05 |
| Jiefeng Gu | — | — | 2020-08 |
| Jinqiu Tang | — | — | 2022-05 |
| Pu Xing | — | — | 2020-08 |
| Ren Luo | — | — | 2020-08 |
| Sarah Yu | — | — | 2020-08 |
| Sheng Liu | — | — | 2022-05 |
| Weidong Dai | — | — | 2020-08 |
| XueDong Du | — | — | 2020-08 |
| Yu Chris | — | — | 2020-08 |
AnPac Bio-Medical Science Co., Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| ProActa Inc | Biotechnology | Seed | $4.6M | $22.2M | same sector · same stage |
| InnAVasc Medical, Inc. | Biotechnology | Seed | $4.6M | $21.1M | same sector · same stage |
| Ampel, LLC | Biotechnology | Seed | $4.8M | $16.7M | same sector · same stage |
| Mitosense, Inc. | Biotechnology | Seed | $4.4M | $23.0M | same sector · same stage |
| Oncoscope Inc | Biotechnology | Seed | $5.2M | $20.0M | same sector · same stage |
| Ibex Biosciences, LLC | Biotechnology | Seed | $5.2M | $25.4M | same sector · same stage |
| Neurodyn Life Sciences Inc. | Biotechnology | Seed | $5.2M | $28.9M | same sector · same stage |
| PaxMedica, Inc. | Biotechnology | Seed | $4.2M | $18.7M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Anogen Life Sciences, Inc. | Biotechnology | Pre-Seed | $15.8M | 90% |
| Ancilia Biosciences, Inc. | Biotechnology | Pre-Seed | $9.8M | 90% |
| Anuncia Medical, Inc. | Biotechnology | Series A | $67.5M | 87% |
| Semba Biosciences Inc | Biotechnology | Seed | $133.2M | 87% |
| Meru Biotechnologies, Inc. | Biotechnology | Pre-Seed | $9.2M | 86% |
| AnBio Therapeutics Ltd. | Biotechnology | Series C | $1.6B | 86% |
| Jabez Biosciences, Inc. | Biotechnology | Seed | $993K | 86% |
| BioCurie, Inc. | Biotechnology | Pre-Seed | $1.3M | 86% |
See where AnPac Bio-Medical Science Co., Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at AnPac Bio-Medical Science Co., Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.